Simulations Plus (NASDAQ:SLP) Issues Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Simulations Plus (NASDAQ:SLP) released its earnings results on Wednesday. The technology company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02, Briefing.com reports. Simulations Plus had a return on equity of 7.80% and a net margin of 14.36%. The firm had revenue of $18.70 million for the quarter, compared to analysts’ expectations of $19.73 million. During the same quarter in the prior year, the firm posted $0.18 earnings per share. The company’s quarterly revenue was up 19.9% on a year-over-year basis. Simulations Plus updated its FY25 guidance to $1.07 to $1.20 EPS and its FY 2025 guidance to 1.070-1.200 EPS.

Simulations Plus Stock Down 0.9 %

SLP stock traded down $0.28 during trading on Friday, hitting $30.68. 276,597 shares of the company’s stock traded hands, compared to its average volume of 130,076. The firm has a market capitalization of $613.91 million, a P/E ratio of 64.50 and a beta of 0.69. Simulations Plus has a 1 year low of $29.37 and a 1 year high of $51.22. The business has a fifty day simple moving average of $33.20 and a two-hundred day simple moving average of $40.76.

Insiders Place Their Bets

In other news, Director Walter S. Woltosz sold 20,000 shares of the business’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $31.26, for a total value of $625,200.00. Following the completion of the transaction, the director now directly owns 3,481,592 shares of the company’s stock, valued at approximately $108,834,565.92. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders sold a total of 60,750 shares of company stock worth $2,145,055 over the last 90 days. Company insiders own 20.90% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on SLP shares. Craig Hallum reissued a “buy” rating and set a $56.00 target price on shares of Simulations Plus in a research note on Wednesday, July 3rd. JMP Securities assumed coverage on shares of Simulations Plus in a research report on Tuesday, July 16th. They issued a “market perform” rating for the company. William Blair reaffirmed an “outperform” rating on shares of Simulations Plus in a research report on Thursday. KeyCorp initiated coverage on Simulations Plus in a report on Monday, July 29th. They issued an “overweight” rating and a $47.00 price target for the company. Finally, BTIG Research dropped their price objective on Simulations Plus from $60.00 to $50.00 and set a “buy” rating on the stock in a research note on Thursday. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $54.50.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.